Biotech Stocks to Target: Sarepta Therapeutics, Regeneron Pharma. & Ariad

Biotech stock market news

Here we take a close look at three upcoming Biotech Stocks which have dominated majority of the news in the Biotech Segment. While Sarepta has shown mediocre results in the past few weeks, the stock may be looking for a comeback in the coming times. On the other hand, both Regeneron and Ariad are looking strong as we head into August. Let’s take a closer look at the three stocks.

Sarepta, which focuses on the discovery and development of RNA-based therapeutics for rare and infectious diseases, saw its shares tumbling on 144-week data on its experimental Duchenne muscular dystrophy treatment, eteplirsen.

Investors were disappointed with the 144-week data on decline in walking distance which was considered to be weaker than the 120-week data presented earlier this year. Despite this, Sarepta remains committed to file for regulatory approval in the U.S. by year end.

Regeneron Pharma. & Ariad

Regeneron, which has seen spectacular success with its eye drug – Eylea, may well have a blockbuster candidate in its pipeline – dupilumab. The company and its partner, Sanofi, presented impressive phase IIb data on the experimental eczema treatment. Dupilumab is slated to move into phase III studies later this year.

Ariad’s investors finally had something to cheer about with the FDA lifting a partial clinical hold on the company’s phase II study of Iclusig in patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors. New patients can now be enrolled in this study. Ariad also presented initial data which indicate Iclusig’s anti-tumor activity in patients with advanced GIST, particularly in patients with KIT exon 11 mutations. Shares were up 7.4%.

Biotech News Video

Watch this video for more “Biotech” news.

Biotech Financial News

While nothing specific is lined up, stay tuned for the usual pipeline and regulatory updates. Moreover, with AbbVie upping its offer for Shire, these two companies will be in the news as investors mull the renewed offer. Earnings updates should also start trickling in over the next few days.

Thanks for visiting the TechNews.org website. Be sure to catch all BioTech financial news, bookmark us and check all the videos and news articles regarding Biotech business news.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone